January 01, 2026 a 12:38 pm
BAX: Analysts Ratings - Baxter International Inc.
Baxter International Inc. has maintained a steady presence in the healthcare sector with a diversified product portfolio ranging from dialysis and infusion systems to connected care solutions. Recent analyst ratings indicate a cautious sentiment with a predominant 'Hold' consensus, reflecting potential market challenges or strategic repositioning. The company's extensive global distribution network and ongoing developments hold potential for growth, yet caution remains amid current market conditions.
Historical Stock Grades
The historical data of analyst ratings for Baxter International Inc. as of December 2025 shows a marked preference towards holding the stock. Despite a broad spectrum of products and services offered by the company, market sentiment remains conservative.:
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 2 | |
| Hold | 13 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment regarding Baxter International Inc. shows a visible shift over the months with an increase in 'Hold' positions and a decline in 'Strong Buy' recommendations. This trend suggests a more cautious approach among analysts.
- The total number of ratings has remained relatively stable, with a slight fluctuation in the number of 'Buy' and 'Strong Buy' recommendations.
- A significant increase in 'Hold' ratings indicates a pause in aggressive buying strategies.
- 'Strong Sell' recommendations continue to remain at a negligible level.
Percentage Trends
Recent months have reflected a notable shift in the percentage distribution of analyst recommendations for Baxter International:
- 'Strong Buy' ratings have decreased from earlier highs, now contributing only a small percentage of total recommendations.
- 'Buy' ratings have seen slight variations but predominantly fluctuate between 10% and 20%.
- 'Hold' ratings have increased, indicating a conservative repositioning among analysts, now constituting the majority at about 65%.
- Overall, the data points to a trend towards greater caution and reduced confidence in aggressive stock performance for Baxter.
Latest Analyst Recommendations
The most recent analyst activities reflect a sustained yet cautious stance on the stock:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-02 | Underweight | Underweight | Morgan Stanley |
| 2025-10-31 | Neutral | Neutral | UBS |
| 2025-10-31 | Neutral | Neutral | Goldman Sachs |
| 2025-10-31 | Neutral | Neutral | Citigroup |
| 2025-10-31 | Hold | Buy | Argus Research |
Analyst Recommendations with Change of Opinion
The following recent changes in opinions highlight a shift in market perceptions:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-31 | Hold | Buy | Argus Research |
| 2025-08-04 | Hold | Buy | Stifel |
| 2024-07-15 | Underweight | Equal Weight | Morgan Stanley |
| 2024-05-10 | Hold | Buy | TD Cowen |
| 2023-01-06 | Equal Weight | Overweight | Morgan Stanley |
Interpretation
The current market evaluation of Baxter International Inc. reflects a conservative approach among analysts. Although there is a broad consensus to 'Hold', there is evidence of growing prudence, as indicated by recent downgrades from 'Buy' to 'Hold'. This points to market uncertainties or perceived challenges within Baxter's operational environment. Additionally, the lack of 'Strong Sell' ratings provides a buffer against negative market sentiment, yet the prevalent 'Hold' recommendation suggests a period of observation, awaiting clearer market signals.
Conclusion
Baxter International Inc.'s market positioning, backed by its extensive product offering across global healthcare, is showing a dichotomy between potential and market perceived caution. Analyst sentiment, predominantly 'Hold' with minor buy-side enthusiasm, highlights the current uncertainties facing the company. Despite operational capabilities, the recent trends suggest analysts are reservatively watching for substantive shifts in market dynamics or strategic initiatives that might alter Baxter's trajectory, balancing potential upsides against prevailing market sentiments.